



Date: 09.05.2024

To,  
The Manager  
BSE Limited,  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai-400001

Company Symbol: GVBL  
Scrip Code: 539206

**Subject: - Outcome of the Board Meeting Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 held on today i.e., 09<sup>th</sup> May, 2024**

Dear Sir / Madam,

This is to inform you that the Board of Directors of the Company at their meeting held on **Thursday, 09<sup>th</sup> May, 2024**, at the Registered office of the Company situated at 4 K.M.stone, Berri Chhara Road Vill. Kherka, Musalman, P.O. Tandaheri, Teh Bahadu, Jhajjar, Haryana, India, 124507 to consider and approve the following matter(s): -

1. Considered and approved the standalone Audited financial results of the Company for the quarter and year months ended 31<sup>st</sup> March, 2024. A copy of the said standalone audited financial results along with the Auditor Report of the Statutory Auditor thereon is enclosed herewith;
2. Appointment of Mr. Satendra Kumar Goyal (DIN: 08767544) as an 'Additional Director' in the category of Non-Executive - Independent Director on the Board of Directors of the Company w.e.f., Thursday, 09<sup>th</sup> May, 2024 to hold office for a term of 5 (five) consecutive years upto May 08, 2029, subject to the approval of the shareholders in the General Meeting pursuant to section 149, 150, 152 read with Schedule IV and Section 161(1) read with Companies (Appointment and Qualification of Directors) Rules, 2014 and other applicable provisions, sections, rules of the companies Act, 2013 (including any statutory modifications or re-enactment thereof for the time being in force).

The details required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 2023 attached below as **Annexure A**

3. Considered and approved the appointment of M/s SBR & Co. LLP as Secretarial Auditor of the company for the F.Y. 2023-24.
4. Considered and approved the appointment of Mr. Navjyoti Kumar Jha as Internal Auditor of the company for the F.Y. 2023-24.

# GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]



4 KM Stone, Berri Chhara Road, P.O. Tanda Heri, Tehsil  
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507

genomicvalley@gmail.com

www.genomicvalley.com

+91 9811341542



The meeting of the Board of Directors commenced at 06:40 P.M. and concluded at 07:00 P.M.

This is for your information and record.

Thanking you,  
Yours Faithfully,

For and on behalf of  
Genomic Valley Biotech Limited

Yogesh Agrawal  
Managing Director  
DIN: 01165288

Place: Delhi

**Annexure-A****A. Particulars of Appointment of Mr. Satendra Kumar Goyal as Non-Executive - Independent Director of the Company**

Si. No.	Particulars	Details
a)	Name of Person	Satendra Kumar Goyal
b)	Reason for change viz. appointment, <del>resignation, removal, death or otherwise</del>	Upon the recommendation of the Nomination & Remuneration Committee Mr. Satendra Kumar Goyal, appointed as Additional Director (Non-Executive, Independent) subject to approval of the shareholders in their meeting.
c)	Date of appointment / <del>cessation</del> (as applicable)	09-05-2024
d)	Terms of Appointment	For 5 (five) consecutive years from May 09, 2024 to May 08, 2029
e)	Brief profile (in case of appointment)	Satendra Kumar Goyal is having Experience in the field of Human Resource Management of 25 years. He has completed his post graduate with Degree of Bachelors of Science (BSc.) He started his career at a tender age and has gained exposure to many fields in the past few years enhancing his core skills and expertise. He carries an intellectual personality and has relevant expertise
f)	Disclosure of relationships between directors (in case of appointment of a director)	No Relationship with existing director of the Company.

**Independent Auditor's Report on the Financial Result of  
Genomic Valley Biotech Limited.**

To,  
The Board of Directors of  
Genomic Valley Biotech Limited,  
4 K.M. Stone, Berri Chharra Road,  
Village- Kherka Musalman, P.O. Tandaheri,  
Tehsil- Bahadurgarh, District-Jhajjar, Haryana-124507.

**Subject: Auditor's Report on the Audited Financial Results for the Quarter and year ended  
March 31, 2024**

**Opinion**

We have audited the accompanying statement of financial results of Genomic Valley Biotech Limited ("the Company") for the quarter and year ended 31<sup>st</sup> March, 2024 ("Statement"), attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:


- i. is presented in accordance with the requirements of regulation 33 the Listing Regulations in this regard: and
- ii. gives a true and fair view in conformity with the recognition and measurement Principles laid down in the Indian Accounting Standards ("Ind AS") and other accounting principles generally accepted in India, of the net profit/(loss) and other comprehensive income and other financial information of the Company for the quarter and year then ended 31<sup>st</sup> March, 2024.

**Basis for Opinion**

We conducted our audit of the Statement in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the companies Act, 2013, ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results for the quarter and year ended 31<sup>st</sup> March, 2024 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

**Management's Responsibilities for the Financial Results**

The Statement has been prepared on the basis of the annual financial statements. The management of the Company is responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit/(loss) and other comprehensive income of the Company and other financial information in accordance with the applicable Indian Accounting Standards prescribed under Section 133 of the Act read with- relevant rules issued thereunder and other Accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for



safeguarding of the Assets of the Company and for preventing and detecting frauds and other Irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting Process.

### **Auditor's Responsibilities for the Audit of the Annual Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatement can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference financial statements in place and the operating effectiveness of such controls,
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management of the company.
- Evaluate the appropriateness and reasonableness of disclosure made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulation
- Conclude on the appropriateness of the board of director's use of going concern basis of accounting and, based on audit evidence obtained, whether the material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's reports to the related disclosures in the financial result or, If such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future event or condition may cause the Company, to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Financial Results of the Company to express an opinion on the Financial Result.



We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit,

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

### Other Matters

The Statement includes the results for the quarter ended 31st March, 2024 being the balancing figure between the audited figures in respect of the full financial year ended 31<sup>st</sup> March, 2024 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to limited review by us, as required under the Listing Regulations.

Our opinion on the Statement is not modified in respect of the above matter.

For ANDROS & CO.  
Chartered Accountants



A handwritten signature in blue ink, appearing to read "Bhavuk Garg".

(CA Bhavuk Garg)  
(Partnership Firm)  
(Membership No.-502310)

Place: Delhi  
Date: 09-05-2024

UDIN: 24502310-BJZYKV-9585

**Statement of Asset and Liabilities**

Particulars	As at	
	31-03-24	31-03-23
	Audited	Audited
	Standalone	Standalone
<b>ASSETS</b>		
<b>Non Current Assets</b>		
Property, plant and equipment	20,656	31,581
Capital work in progress	-	-
Other Intangible assets	-	-
Intangible assets under development	-	-
Financial assets	-	-
Investment	1,66,660	-
Loans	1,40,00,000	1,83,50,593
Security Deposits	50,000	50,000
Other financial assets	-	-
Deferred tax assets (Net)	-	-
Other non current assets	-	-
<b>Total Non-Current Assets</b>	<b>1,42,37,316</b>	<b>1,84,32,174</b>
<b>Current Assets</b>		
Inventories	-	-
Financial Assets:	-	-
Investments	-	-
Trade Receivables	2,53,01,145	2,21,74,825
Cash and Cash equivalents	22,844	-
Other Balances with banks	37,890	4,13,092
Loans	-	-
Other financial assets	-	-
Other Current assets	37,37,529	31,83,821
<b>Total Current Assets</b>	<b>2,90,99,408</b>	<b>2,57,71,738</b>
<b>Total Assets</b>	<b>4,33,36,724</b>	<b>4,42,03,912</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity Share Capital	3,05,45,000	3,05,45,000
Other Equity	48,75,601	47,23,782
<b>Total Equity</b>	<b>3,54,20,601</b>	<b>3,52,68,782</b>
<b>Non Current Liabilities</b>		
Financial liabilities		
Borrowings	-	-
Security Deposits	-	-
Other Financials liabilities	-	-
Deferred tax liabilities (Net)	1,840	2,178
Provisions	-	-
Other Non Current liabilities	-	-
<b>Total Non Current Liabilities</b>	<b>1,840</b>	<b>2,178</b>
<b>Current Liabilities</b>		
Financial liabilities		
Borrowings	-	-
Trade Payables	60,19,146	61,06,203
Other Financials liabilities	-	-
Provisions	25,000	54,000
Other Current liabilities	18,70,137	27,72,749
<b>Total Current Liabilities</b>	<b>79,14,283</b>	<b>89,32,952</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>4,33,36,724</b>	<b>4,42,03,912</b>

**Notes :**

- The above Financial Results were reviewed by the Members of Audit Committee and approved by the Board of Directors at their respective Meeting held on May 29, 2023 and the Statutory Auditors of the company have audited these financials results.
- The Company has adopted Indian Accounting Standards (Ind AS) notified by Ministry of Corporate Affairs from 1st April 2017, with a transition date 1st April 2016 and accordingly these financial Result have been prepared in accordance with the companies (Indian Accounting Standard) Rules, 2015 prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India.
- Company's Business activity falls within a single business segment i.e. Horticulture in terms of Ind-AS 108 on Segment Reporting.
- Figures for the prior period have been regrouped and / or rearranged wherever considered necessary as per the revised format prescribed by SEBI under SEBI (LODR) Regulations, 2015 and amended as per the Schedule III of the Companies Act, 2013.
- The intangible asset namely "domain" will be ammortised over 4 years of useful life.

For and on behalf of the Board of Directors of  
Genomic Valley Biotech Limited



*Yogesh Agrawal*  
Yogesh Agrawal  
Chairman and Managing Director  
DIN: 01165288  
Address: G-74, Pushkar Enclave,  
Paschim Vihar, New Delhi-110063

Place : Delhi  
Dated : 09-05-2024

**GENOMIC VALLEY BIOTECH LIMITED**

REGD. OFF: 4 K.M. STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI, TEHSIL BAHADURGARH, DISTT. JHAJJAR, HARYANA-124507

CIN: L01122HR1994PLC033029

**CASH FLOW STATEMENT FOR THE PERIOD ENDED 31 March, 2024**

	Particulars	Amount in INR	
		31.03.2024	31.03.2023
<b>A.</b>	<b>CASH FLOW FROM OPERATING ACTIVITIES</b>		
	Net Profit As Statement Profit & Loss	1,51,480	91,31,783
	<b>Adjustment For</b>		
	Discount received	-	-
	Non-Operating Income	-15,003	-
	Interest Income	-	-4,25,453
	Loss on sale of assets	-	-
	Depreciation and Amortisation Expenses	10,925	79,243
	<b>Operating Profit Before Change in Working Capital</b>	<b>1,47,402</b>	<b>87,85,573</b>
	<b>ADJUSTMENTS FOR WORKING CAPITAL:</b>		
	Increase/Decrease in Loans and Advances	43,50,593	-93,50,593
	Decrease/ (Increase) in Inventories	-	-
	Increase/Decrease in Security Deposits	-	-
	Increase/Decrease in Trade Receivables	-31,26,320	-2,21,74,825
	Increase/Decrease in Other Current Assets	-5,53,708	81,63,222
	Increase/Decrease in Current Liabilities	-10,18,669	67,89,970
	<b>CASH GENERATED FROM OPERATIONS</b>	<b>-2,00,702</b>	<b>-77,86,652</b>
	Taxes Paid		
	<b>Total (A)</b>	<b>-2,00,702</b>	<b>-77,86,652</b>
<b>B.</b>	<b>CASH FLOW FROM INVESTING ACTIVITIES</b>		
	Additions/Sales to fixed assets	-	1,47,92,500
	Purchase/Sell of Investments	-1,66,660	-
	Discount received	-	-
	Non-Operating Income	15,003	-
	Interest Income	-	4,25,453
	<b>Total (B)</b>	<b>-1,51,657</b>	<b>1,52,17,953</b>
<b>C.</b>	<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
	Proceeds from Borrowings	-	-70,45,000
	Preliminary Expenses	-	-
	<b>Total (C)</b>	<b>-</b>	<b>-70,45,000</b>
	<b>NET CASH FLOWS DURING THE YEAR (A+B+C)</b>	<b>-3,52,358</b>	<b>3,86,301</b>
	Cash and Cash Equivalents (Opening Balance)	4,13,092	26,791
	Cash and Cash Equivalents (Closing Balance)	60,734	4,13,092

**For Genomic Valley Biotech Limited**

*(Signature)*  
**Managing Director / Director**





**GENOMIC VALLEY BIOTECH LIMITED**  
**Regd. Off: 4 K.M. STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI,**  
**TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507**  
**CIN: L01122HK1994PLC033029**

Statement of Standalone Audited Financials Results for the quarter and year ended March 31, 2024

In Rs.

Sr. No.	Particular	For the quarter ended			For the year ended	
		31-Mar-24 Audited	31-Dec-23 Un-Audited	31-Mar-23 Audited	31-Mar-24 Audited	31-Mar-23 Audited
I	Revenue From Operations	-	3,90,000	99,60,750	16,50,750	2,72,25,190
II	Other Income	-	-	1,20,576	15,003	4,25,453
III	<b>Total Revenue (I+II)</b>	-	<b>3,90,000</b>	<b>1,00,81,326</b>	<b>16,65,753</b>	<b>2,76,50,643</b>
IV	<b>Expenses</b>					
	Cost of materials consumed	-	-	-	-	-
	Purchases of Stock-in-Trade	-	-	-	-	1,58,36,800
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	-	-	-	-	-
	Employee benefits expense	45,000	45,000	3,37,590	3,75,000	14,96,087
	Financial costs	-	-	-	-	-
	Depreciation and amortization expense	2,732	2,731	-73,405	10,925	79,243
	Other expenses	3,98,600	1,24,702	3,00,120	11,28,348	11,06,730
	<b>Total Expenses (IV)</b>	<b>4,46,332</b>	<b>1,72,433</b>	<b>5,64,305</b>	<b>15,14,273</b>	<b>1,85,18,860</b>
V	<b>Profit / (Loss) before exceptional item and tax (III-IV)</b>	<b>-4,46,332</b>	<b>2,17,567</b>	<b>95,17,021</b>	<b>1,51,480</b>	<b>91,31,783</b>
VI	Exceptional Item	-	-	2,85,048	-	26,43,164
VII	<b>Profit/Loss before Tax (V-VI)</b>	<b>-4,46,332</b>	<b>2,17,567</b>	<b>98,02,069</b>	<b>1,51,480</b>	<b>64,88,619</b>
VIII	<b>Tax expenses</b>					
	(1) Current Tax	-	-	-	-	-
	(2) Deferred Tax	-339	-	6,080	-339	6,080
IX	<b>Profit/ (Loss) for the period from continuing operations (VII-VIII)</b>	<b>-4,45,993</b>	<b>2,17,567</b>	<b>97,95,989</b>	<b>1,51,818</b>	<b>64,82,539</b>
X	Profit/ (Loss) from discontinued operations	-	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-	-
XII	<b>Profit/ (Loss) from discontinuing operations (after tax) (X-XI)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
XIII	<b>Profit/Loss for the period (IX+XII)</b>	<b>-4,45,993</b>	<b>2,17,567</b>	<b>97,95,989</b>	<b>1,51,818</b>	<b>64,82,539</b>
XIV	<b>Other Comprehensive Income</b>					
A	(i) Items that will not be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
B	(i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
XV	<b>Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit/ (Loss) and other Comprehensive Income for the period)</b>	<b>-4,45,993</b>	<b>2,17,567</b>	<b>97,95,989</b>	<b>1,51,818</b>	<b>64,82,539</b>
XVI	<b>Paid up Equity Share Capital, Equity Share of ₹ 10/- each</b>	<b>30,54,500</b>	<b>30,54,500</b>	<b>30,54,500</b>	<b>30,54,500</b>	<b>30,54,500</b>
XVII	<b>Earning Per Equity Share (for continuing operation):</b>					
	1) Basic	-0.15	0.07	3.21	0.05	2.12
	2) Diluted	-0.15	0.07	3.21	0.05	2.12
XVIII	<b>Earning Per Equity Share (for discontinued operation):</b>					
	1) Basic	0.00	0.00	0.00	0.00	0.00
	2) Diluted	0.00	0.00	0.00	0.00	0.00
XIX	<b>Earning Per Equity Share (for discontinued &amp; continuing operations):</b>					
	1) Basic	-0.15	0.07	3.21	0.05	2.12
	2) Diluted	-0.15	0.07	3.21	0.05	2.12

**For Genomic Valley Biotech Limited**

**Managing Director / Director**



# GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]

4 KM Stone, Beri Chhara Road, P.O. Tanda Heri, Tehsil  
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507

genomicvalley@gmail.com

www.genomicvalley.com

+91 9811341542



May 09, 2024

To  
BSE Ltd.  
P. J. Towers, Dala Street,  
Mumbai – 400001  
Scrip Code: 539206

Sub: Declaration on Audit Reports with an unmodified opinion

Dear Sir/ Madam,

Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare that M/s ANDROS & CO., Chartered Accountants (Firm Registration No. 008976N), Statutory Auditors of the Company, have issued Audit Reports with an unmodified opinion on the Audited Standalone Financial Results of the Company for the year ended March 31, 2024.

Kindly take the same on record.

Thanking you.

For Genomic Valley Biotech Limited



Yogesh Agrawal  
Chairman & Managing Director  
DIN: 01165288  
Add: G-74, Pushkar Enclave,  
Paschim Vihar Delhi – 110063

Investor E-mail id: [genomicvalley@gmail.com](mailto:genomicvalley@gmail.com)